Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Identifying Cancer Biomarkers for Immunotherapy Response
Clinical Breakthroughs

Identifying Cancer Biomarkers for Immunotherapy Response

By Melissa RohmanNov 24, 2021
Share
Facebook Twitter Email
Amy Heimberger, MD, the Jean Malnati Miller Professor of Brain Tumor Research, professor of Neurological Surgery and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study published in Science Translational Medicine.

Scientists have discovered a potential biomarker that could more accurately identify which patients with non-hypermutated cancers will respond to specialized immunotherapy drugs called immune checkpoint inhibitors, according to findings published in Science Translational Medicine.

Amy Heimberger, MD, the Jean Malnati Miller Professor of Brain Tumor Research and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study.

Immune checkpoint blockade (ICB) therapy has demonstrated significant clinical benefit for a subset of patients with hypermutated cancer types, such as melanoma or lung cancer.

ICB therapy utilizes immune checkpoint inhibitor drugs that block specific proteins on cancer and immune cells called checkpoints. These proteins keep the immune response from becoming too strong, but may also prevent T-cells from killing cancer cells.

Immune checkpoint inhibitors help reinvigorate T-cells, restoring their immune activity and helping them kill cancer cells more efficiently. For some cancers, however, T-cells become overstimulated or “exhausted,” to the point where immune checkpoint inhibitors are unable to restore T-cell function at all.

“So, the real question is who benefits from an immune checkpoint inhibitor and who doesn’t benefit, because there can be toxicities associated with these drugs,” said Heimberger, who is also a professor of Neurological Surgery and scientific director of the Lou and Jean Malnati Brain Tumor Institute of the Lurie Cancer Center.

Previous research has identified several biomarkers to help determine which patients with hypermutated cancers benefit from ICB therapy, with one of these biomarkers being tumor mutational burden, or the number of mutations in the DNA of cancer cells.

However, recent work, of which Heimberger was also a co-author, discovered that high tumor mutational burden does not accurately predict which patients with non-hypermutated cancers will best respond to ICB therapy. These findings established momentum for the current study, where Heimberger and collaborators aimed to identify biomarkers in non-hypermutated cancers that are predictive of ICB response.

In the study, investigators analyzed 12 cohorts of patients with non-hypermutated tumors across seven cancer types, including breast, prostate, kidney and brain cancer.

Cancer cells that expressed defects in the replication stress response (RSR) — when a cell’s genome is exposed to stresses during DNA replication, resulting in compromising genetic mutations — were associated with ICB response in the 12 patient cohorts.

Next, using mouse models of breast cancer containing a low replication stress response signature, the investigators pharmacologically induced the replication stress response in the tumor cells, demonstrating that they could successfully modulate a response to ICB therapy.

The findings demonstrate that the RSR defect gene signature is a potential biomarker for identifying patients with non-hypermutated tumor types who may benefit from ICB therapy. More so, pharmacologically inducing RSR may also be a promising therapeutic approach to increase the number of patients who benefit from ICB therapy, but further research is still needed, according to the authors.

“There are four key elements of an anti-tumor immune response: activation of the immune system, a target in the cancer that the immune system can go after, sufficient trafficking to that tumor’s microenvironment and maintenance of that effect or response in the tumor microenvironment,” Heimberger said. “What is required for us to get a definitive, clear biomarker for treatment response is a comprehensive biomarker that interrogates the entire system. This is a step in the right direction, but it’s not complete.”

“Though it would be extremely useful to identify the 10 to 20 percent of patients who may benefit from ICB, the ability to sensitize the remaining 80 to 90 percent that would otherwise be resistant to ICB has the potential to improve outcomes for much larger patient populations,” said Daniel McGrail, PhD, a postdoctoral fellow at The University of Texas MD Anderson Cancer Center and first author of the study.

Support for this work was provided by the Department of Defense Era of Hope Scholar Award grant W81XWH-10-1-0558, the George and Barbara Bush Endowment for Innovative Cancer Research and the National Cancer Institute grant R01CA247862.

Cancer Neurosurgery Research
Share. Facebook Twitter Email

Related Posts

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

Comments are closed.

Latest News

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.